EPI-7170

EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs) . EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC) [1].

Product Specifications

CAS Number

[2139288-26-7]

UNSPSC

12352005

Target

Androgen Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/epi-7170.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C1=CC(Cl)=C(C(Cl)=C1)OC[C@H](O)CCl)(C2=CC=C(C=C2)OC[C@H](O)CNS(C)(=O)=O)C

Molecular Formula

C22H28Cl3NO6S

Molecular Weight

540.88

References & Citations

[1]Hirayama Y, et al. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. Mol Oncol. 2020 Oct;14 (10) :2455-2470.